<!doctype html><html lang=en><head><meta charset=utf-8><meta name=description content="Definition & Risk Factors  ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ autoimmune ‡∏ó‡∏±‡πâ‡∏á CMI, HMI ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á > ‡∏ú‡∏π‡πâ‡∏ä‡∏≤‡∏¢ ‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô ‡πÄ‡∏ä‡πà‡∏ô estrogen ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ß‡∏±‡∏¢‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡πå‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏°‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á ‡∏™‡∏¥‡πà‡∏á‡πÅ‡∏ß‡∏î‡∏•‡πâ‡∏≠‡∏° ‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Å‡πá‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á  ‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÑ‡∏õ‡∏ô‡∏≤‡∏ô ‡πÜ ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô self-tolerance ‡∏Ç‡∏≠‡∏á innate immunity ‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î auto-antibodies production   ‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ EBV UV  Pathophysiology and Clinical Features  ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô‡∏ï‡πà‡∏≠ nucleus ‡∏Ç‡∏≠‡∏á‡πÄ‡∏ã‡∏•‡∏•‡πå (autoantibody) ‡πÄ‡∏ä‡πà‡∏ô anti-dsDNA ‡πÅ‡∏•‡∏∞ anti-Sm immune complex ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏õ‡∏ï‡∏Å‡∏ï‡∏∞‡∏Å‡∏≠‡∏ô‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ô‡∏±‡πâ‡∏ô ‡πÜ ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏≤‡∏á‡∏Ç‡πâ‡∏≠‡πÅ‡∏•‡∏∞‡∏ú‡∏¥‡∏ß‡∏´‡∏ô‡∏±‡∏á (90%) ‡∏ã‡∏∂‡πà‡∏á‡∏´‡∏≤‡∏Å‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏µ‡πÅ‡∏Ñ‡πà 2 ‡∏£‡∏∞‡∏ö‡∏ö‡∏ô‡∏µ‡πâ prognosis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏î‡∏µ ‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡∏ï‡∏£‡∏á‡∏Å‡∏±‡∏ô‡∏Ç‡πâ‡∏≤‡∏° ‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏£‡∏∞‡∏ö‡∏ö‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô CNS ‡∏´‡∏£‡∏∑‡∏≠ renal ‡∏°‡∏±‡∏Å‡∏à‡∏∞ prognosis ‡∏´‡πà‡∏ß‡∏¢‡πÅ‡∏ï‡∏Å  Skin  ‡∏à‡∏∞‡∏°‡∏µ‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏à‡∏≤‡∏∞‡∏à‡∏á‡∏Å‡∏±‡∏ö‡πÇ‡∏£‡∏Ñ acute LE  malar rash or butterfly rash : ‡πÄ‡∏õ‡πâ‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì nasolabial folds bullous LE ‡πÄ‡∏õ‡πá‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ï‡∏∏‡πà‡∏°‡∏ô‡πâ‡∏≥   subacute LE  psoriatic like, ‡∏ß‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏ö‡πÅ‡∏î‡∏á ‡∏Å‡∏•‡∏≤‡∏á‡∏Ç‡∏≤‡∏ß   chronic LE  discoid rash  ‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏™‡πÄ‡∏Å‡πá‡∏î‡πÄ‡∏á‡∏¥‡∏ô‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡∏°‡∏µ‡∏™‡πÄ‡∏Å‡πá‡∏î ‡∏û‡∏ö hair scaring ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≠‡∏°‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡πÅ‡∏•‡∏∞‡∏£‡∏π‡∏Ç‡∏∏‡∏°‡∏Ç‡∏ô‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏ó‡∏•‡∏≤‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏°‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏Ç‡∏≤‡∏ß      Joint  arthritis ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 2 ‡∏Ç‡πâ‡∏≠ ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA +- ‡∏õ‡∏ß‡∏î ‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á ‡∏ú‡∏• film ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÄ‡∏à‡∏≠ erosion!"><meta property="og:title" content><meta property="og:description" content="Definition & Risk Factors  ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ autoimmune ‡∏ó‡∏±‡πâ‡∏á CMI, HMI ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á > ‡∏ú‡∏π‡πâ‡∏ä‡∏≤‡∏¢ ‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô ‡πÄ‡∏ä‡πà‡∏ô estrogen ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ß‡∏±‡∏¢‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡πå‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏°‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á ‡∏™‡∏¥‡πà‡∏á‡πÅ‡∏ß‡∏î‡∏•‡πâ‡∏≠‡∏° ‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Å‡πá‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á  ‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÑ‡∏õ‡∏ô‡∏≤‡∏ô ‡πÜ ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô self-tolerance ‡∏Ç‡∏≠‡∏á innate immunity ‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î auto-antibodies production   ‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ EBV UV  Pathophysiology and Clinical Features  ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô‡∏ï‡πà‡∏≠ nucleus ‡∏Ç‡∏≠‡∏á‡πÄ‡∏ã‡∏•‡∏•‡πå (autoantibody) ‡πÄ‡∏ä‡πà‡∏ô anti-dsDNA ‡πÅ‡∏•‡∏∞ anti-Sm immune complex ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏õ‡∏ï‡∏Å‡∏ï‡∏∞‡∏Å‡∏≠‡∏ô‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ô‡∏±‡πâ‡∏ô ‡πÜ ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏≤‡∏á‡∏Ç‡πâ‡∏≠‡πÅ‡∏•‡∏∞‡∏ú‡∏¥‡∏ß‡∏´‡∏ô‡∏±‡∏á (90%) ‡∏ã‡∏∂‡πà‡∏á‡∏´‡∏≤‡∏Å‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏µ‡πÅ‡∏Ñ‡πà 2 ‡∏£‡∏∞‡∏ö‡∏ö‡∏ô‡∏µ‡πâ prognosis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏î‡∏µ ‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡∏ï‡∏£‡∏á‡∏Å‡∏±‡∏ô‡∏Ç‡πâ‡∏≤‡∏° ‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏£‡∏∞‡∏ö‡∏ö‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô CNS ‡∏´‡∏£‡∏∑‡∏≠ renal ‡∏°‡∏±‡∏Å‡∏à‡∏∞ prognosis ‡∏´‡πà‡∏ß‡∏¢‡πÅ‡∏ï‡∏Å  Skin  ‡∏à‡∏∞‡∏°‡∏µ‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏à‡∏≤‡∏∞‡∏à‡∏á‡∏Å‡∏±‡∏ö‡πÇ‡∏£‡∏Ñ acute LE  malar rash or butterfly rash : ‡πÄ‡∏õ‡πâ‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì nasolabial folds bullous LE ‡πÄ‡∏õ‡πá‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ï‡∏∏‡πà‡∏°‡∏ô‡πâ‡∏≥   subacute LE  psoriatic like, ‡∏ß‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏ö‡πÅ‡∏î‡∏á ‡∏Å‡∏•‡∏≤‡∏á‡∏Ç‡∏≤‡∏ß   chronic LE  discoid rash  ‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏™‡πÄ‡∏Å‡πá‡∏î‡πÄ‡∏á‡∏¥‡∏ô‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡∏°‡∏µ‡∏™‡πÄ‡∏Å‡πá‡∏î ‡∏û‡∏ö hair scaring ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≠‡∏°‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡πÅ‡∏•‡∏∞‡∏£‡∏π‡∏Ç‡∏∏‡∏°‡∏Ç‡∏ô‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏ó‡∏•‡∏≤‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏°‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏Ç‡∏≤‡∏ß      Joint  arthritis ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 2 ‡∏Ç‡πâ‡∏≠ ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA +- ‡∏õ‡∏ß‡∏î ‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á ‡∏ú‡∏• film ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÄ‡∏à‡∏≠ erosion!"><meta property="og:type" content="website"><meta property="og:image" content="https://quartz.jzhao.xyz/icon.png"><meta property="og:url" content="https://quartz.jzhao.xyz/notes/25-SLE/"><meta property="og:width" content="200"><meta property="og:height" content="200"><meta name=twitter:card content="summary"><meta name=twitter:title content><meta name=twitter:description content="Definition & Risk Factors  ‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ autoimmune ‡∏ó‡∏±‡πâ‡∏á CMI, HMI ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á > ‡∏ú‡∏π‡πâ‡∏ä‡∏≤‡∏¢ ‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô ‡πÄ‡∏ä‡πà‡∏ô estrogen ‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ß‡∏±‡∏¢‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡πå‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ ‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏°‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á ‡∏™‡∏¥‡πà‡∏á‡πÅ‡∏ß‡∏î‡∏•‡πâ‡∏≠‡∏° ‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Å‡πá‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á  ‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÑ‡∏õ‡∏ô‡∏≤‡∏ô ‡πÜ ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô self-tolerance ‡∏Ç‡∏≠‡∏á innate immunity ‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î auto-antibodies production   ‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ EBV UV  Pathophysiology and Clinical Features  ‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô‡∏ï‡πà‡∏≠ nucleus ‡∏Ç‡∏≠‡∏á‡πÄ‡∏ã‡∏•‡∏•‡πå (autoantibody) ‡πÄ‡∏ä‡πà‡∏ô anti-dsDNA ‡πÅ‡∏•‡∏∞ anti-Sm immune complex ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏õ‡∏ï‡∏Å‡∏ï‡∏∞‡∏Å‡∏≠‡∏ô‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ô‡∏±‡πâ‡∏ô ‡πÜ ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏≤‡∏á‡∏Ç‡πâ‡∏≠‡πÅ‡∏•‡∏∞‡∏ú‡∏¥‡∏ß‡∏´‡∏ô‡∏±‡∏á (90%) ‡∏ã‡∏∂‡πà‡∏á‡∏´‡∏≤‡∏Å‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏µ‡πÅ‡∏Ñ‡πà 2 ‡∏£‡∏∞‡∏ö‡∏ö‡∏ô‡∏µ‡πâ prognosis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏î‡∏µ ‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡∏ï‡∏£‡∏á‡∏Å‡∏±‡∏ô‡∏Ç‡πâ‡∏≤‡∏° ‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏£‡∏∞‡∏ö‡∏ö‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô CNS ‡∏´‡∏£‡∏∑‡∏≠ renal ‡∏°‡∏±‡∏Å‡∏à‡∏∞ prognosis ‡∏´‡πà‡∏ß‡∏¢‡πÅ‡∏ï‡∏Å  Skin  ‡∏à‡∏∞‡∏°‡∏µ‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏à‡∏≤‡∏∞‡∏à‡∏á‡∏Å‡∏±‡∏ö‡πÇ‡∏£‡∏Ñ acute LE  malar rash or butterfly rash : ‡πÄ‡∏õ‡πâ‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì nasolabial folds bullous LE ‡πÄ‡∏õ‡πá‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ï‡∏∏‡πà‡∏°‡∏ô‡πâ‡∏≥   subacute LE  psoriatic like, ‡∏ß‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏ö‡πÅ‡∏î‡∏á ‡∏Å‡∏•‡∏≤‡∏á‡∏Ç‡∏≤‡∏ß   chronic LE  discoid rash  ‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏™‡πÄ‡∏Å‡πá‡∏î‡πÄ‡∏á‡∏¥‡∏ô‡πÄ‡∏•‡πá‡∏Å ‡πÜ ‡∏°‡∏µ‡∏™‡πÄ‡∏Å‡πá‡∏î ‡∏û‡∏ö hair scaring ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≠‡∏°‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡πÅ‡∏•‡∏∞‡∏£‡∏π‡∏Ç‡∏∏‡∏°‡∏Ç‡∏ô‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏ó‡∏•‡∏≤‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏°‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏Ç‡∏≤‡∏ß      Joint  arthritis ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 2 ‡∏Ç‡πâ‡∏≠ ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA +- ‡∏õ‡∏ß‡∏î ‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á ‡∏ú‡∏• film ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÄ‡∏à‡∏≠ erosion!"><meta name=twitter:image content="https://quartz.jzhao.xyz/icon.png"><title>ü™¥ Harit's External Brain</title><meta name=viewport content="width=device-width,initial-scale=1"><link rel="shortcut icon" type=image/png href=https://quartz.jzhao.xyz//icon.png><link href=https://quartz.jzhao.xyz/styles.b369a84b3c6e6bfd686ad1f9da65641c.min.css rel=stylesheet><link href=https://quartz.jzhao.xyz/styles/_light_syntax.86a48a52faebeaaf42158b72922b1c90.min.css rel=stylesheet id=theme-link><script src=https://quartz.jzhao.xyz/js/darkmode.63d6a3e095d0bd2b935b62adec9dc11b.min.js></script>
<script src=https://quartz.jzhao.xyz/js/util.a0ccf91e1937fe761a74da4946452710.min.js></script>
<link rel=preload href=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.css as=style onload='this.onload=null,this.rel="stylesheet"' integrity=sha384-R4558gYOUz8mP9YWpZJjofhk+zx0AS11p36HnD2ZKj/6JR5z27gSSULCNHIRReVs crossorigin=anonymous><script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/katex.min.js integrity=sha384-z1fJDqw8ZApjGO3/unPWUPsIymfsJmyrDVWC8Tv/a1HeOtGmkwNd/7xUS0Xcnvsx crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.15.1/dist/contrib/auto-render.min.js integrity=sha384-+XBljXPPiv+OzfbB3cVmLHf4hdUFHlWNZN5spNQ7rmHTXpd7WvJum6fIACpNNfIR crossorigin=anonymous></script>
<script defer src=https://cdn.jsdelivr.net/npm/katex@0.16.2/dist/contrib/copy-tex.min.js integrity=sha384-ww/583aHhxWkz5DEVn6OKtNiIaLi2iBRNZXfJRiY1Ai7tnJ9UXpEsyvOITVpTl4A crossorigin=anonymous></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/core@1.2.1></script>
<script src=https://cdn.jsdelivr.net/npm/@floating-ui/dom@1.2.1></script>
<script async src=https://quartz.jzhao.xyz/js/popover.aa9bc99c7c38d3ae9538f218f1416adb.min.js></script>
<script defer src=https://quartz.jzhao.xyz/js/code-title.ce4a43f09239a9efb48fee342e8ef2df.min.js></script>
<script defer src=https://quartz.jzhao.xyz/js/clipboard.2913da76d3cb21c5deaa4bae7da38c9f.min.js></script>
<script defer src=https://quartz.jzhao.xyz/js/callouts.7723cac461d613d118ee8bb8216b9838.min.js></script>
<script>const SEARCH_ENABLED=!1,LATEX_ENABLED=!0,PRODUCTION=!0,BASE_URL="https://quartz.jzhao.xyz/",fetchData=Promise.all([fetch("https://quartz.jzhao.xyz/indices/linkIndex.76839aeab22f36bdfd6d4f87a3220fdf.min.json").then(e=>e.json()).then(e=>({index:e.index,links:e.links})),fetch("https://quartz.jzhao.xyz/indices/contentIndex.f7a69e625ab780672aca4c4a14b049a7.min.json").then(e=>e.json())]).then(([{index:e,links:t},n])=>({index:e,links:t,content:n})),render=()=>{const e=new URL(BASE_URL),t=e.pathname,n=window.location.pathname,s=t==n;addCopyButtons(),addTitleToCodeBlocks(),addCollapsibleCallouts(),initPopover("https://quartz.jzhao.xyz",!0);const o=document.getElementById("footer");if(o){const e=document.getElementById("graph-container");if(!e)return requestAnimationFrame(render);e.textContent="";const t=s&&!1;drawGraph("https://quartz.jzhao.xyz",t,[{"/moc":"#4388cc"}],t?{centerForce:1,depth:-1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.5,linkDistance:1,opacityScale:3,repelForce:1,scale:1.4}:{centerForce:1,depth:1,enableDrag:!0,enableLegend:!1,enableZoom:!0,fontSize:.6,linkDistance:1,opacityScale:3,repelForce:2,scale:1.2})}var i=document.getElementsByClassName("mermaid");i.length>0&&import("https://unpkg.com/mermaid@9/dist/mermaid.esm.min.mjs").then(e=>{e.default.init()});function a(n){const e=n.target,t=e.className.split(" "),s=t.includes("broken"),o=t.includes("internal-link");plausible("Link Click",{props:{href:e.href,broken:s,internal:o,graph:!1}})}const r=document.querySelectorAll("a");for(link of r)link.className.includes("root-title")&&link.addEventListener("click",a,{once:!0})},init=(e=document)=>{addCopyButtons(),addTitleToCodeBlocks(),renderMathInElement(e.body,{delimiters:[{left:"$$",right:"$$",display:!0},{left:"$",right:"$",display:!1}],macros:{'‚Äô':"'"},throwOnError:!1})}</script><script type=module>
    import { attachSPARouting } from "https:\/\/quartz.jzhao.xyz\/js\/router.d6fe6bd821db9ea97f9aeefae814d8e7.min.js"
    attachSPARouting(init, render)
  </script><script defer data-domain=quartz.jzhao.xyz src=https://plausible.io/js/script.js></script>
<script>window.plausible=window.plausible||function(){(window.plausible.q=window.plausible.q||[]).push(arguments)}</script></head><body><div id=search-container><div id=search-space><input autocomplete=off id=search-bar name=search type=text aria-label=Search placeholder="Search for something..."><div id=results-container></div></div></div><script src=https://cdn.jsdelivr.net/npm/flexsearch@0.7.21/dist/flexsearch.bundle.js integrity="sha256-i3A0NZGkhsKjVMzFxv3ksk0DZh3aXqu0l49Bbh0MdjE=" crossorigin=anonymous defer></script>
<script defer src=https://quartz.jzhao.xyz/js/full-text-search.e6e2e0c213187ca0c703d6e2c7a77fcd.min.js></script><div class=singlePage><header><h1 id=page-title><a class=root-title href=https://quartz.jzhao.xyz/>ü™¥ Harit's External Brain</a></h1><div class=spacer></div><div id=search-icon><p>Search</p><svg tabindex="0" aria-labelledby="title desc" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 19.9 19.7"><title id="title">Search Icon</title><desc id="desc">Icon to open search</desc><g class="search-path" fill="none"><path stroke-linecap="square" d="M18.5 18.3l-5.4-5.4"/><circle cx="8" cy="8" r="7"/></g></svg></div><div class=darkmode><input class=toggle id=darkmode-toggle type=checkbox tabindex=-1>
<label id=toggle-label-light for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="dayIcon" viewBox="0 0 35 35" style="enable-background:new 0 0 35 35"><title>Light Mode</title><path d="M6 17.5C6 16.672 5.328 16 4.5 16h-3C.672 16 0 16.672.0 17.5S.672 19 1.5 19h3C5.328 19 6 18.328 6 17.5zM7.5 26c-.414.0-.789.168-1.061.439l-2 2C4.168 28.711 4 29.086 4 29.5 4 30.328 4.671 31 5.5 31c.414.0.789-.168 1.06-.44l2-2C8.832 28.289 9 27.914 9 27.5 9 26.672 8.329 26 7.5 26zm10-20C18.329 6 19 5.328 19 4.5v-3C19 .672 18.329.0 17.5.0S16 .672 16 1.5v3C16 5.328 16.671 6 17.5 6zm10 3c.414.0.789-.168 1.06-.439l2-2C30.832 6.289 31 5.914 31 5.5 31 4.672 30.329 4 29.5 4c-.414.0-.789.168-1.061.44l-2 2C26.168 6.711 26 7.086 26 7.5 26 8.328 26.671 9 27.5 9zM6.439 8.561C6.711 8.832 7.086 9 7.5 9 8.328 9 9 8.328 9 7.5c0-.414-.168-.789-.439-1.061l-2-2C6.289 4.168 5.914 4 5.5 4 4.672 4 4 4.672 4 5.5c0 .414.168.789.439 1.06l2 2.001zM33.5 16h-3c-.828.0-1.5.672-1.5 1.5s.672 1.5 1.5 1.5h3c.828.0 1.5-.672 1.5-1.5S34.328 16 33.5 16zM28.561 26.439C28.289 26.168 27.914 26 27.5 26c-.828.0-1.5.672-1.5 1.5.0.414.168.789.439 1.06l2 2C28.711 30.832 29.086 31 29.5 31c.828.0 1.5-.672 1.5-1.5.0-.414-.168-.789-.439-1.061l-2-2zM17.5 29c-.829.0-1.5.672-1.5 1.5v3c0 .828.671 1.5 1.5 1.5s1.5-.672 1.5-1.5v-3C19 29.672 18.329 29 17.5 29zm0-22C11.71 7 7 11.71 7 17.5S11.71 28 17.5 28 28 23.29 28 17.5 23.29 7 17.5 7zm0 18c-4.136.0-7.5-3.364-7.5-7.5s3.364-7.5 7.5-7.5 7.5 3.364 7.5 7.5S21.636 25 17.5 25z"/></svg></label><label id=toggle-label-dark for=darkmode-toggle tabindex=-1><svg xmlns="http://www.w3.org/2000/svg" xmlns:xlink="http://www.w3.org/1999/xlink" id="nightIcon" viewBox="0 0 100 100" style="enable-background='new 0 0 100 100'"><title>Dark Mode</title><path d="M96.76 66.458c-.853-.852-2.15-1.064-3.23-.534-6.063 2.991-12.858 4.571-19.655 4.571C62.022 70.495 50.88 65.88 42.5 57.5 29.043 44.043 25.658 23.536 34.076 6.47c.532-1.08.318-2.379-.534-3.23-.851-.852-2.15-1.064-3.23-.534-4.918 2.427-9.375 5.619-13.246 9.491-9.447 9.447-14.65 22.008-14.65 35.369.0 13.36 5.203 25.921 14.65 35.368s22.008 14.65 35.368 14.65c13.361.0 25.921-5.203 35.369-14.65 3.872-3.871 7.064-8.328 9.491-13.246C97.826 68.608 97.611 67.309 96.76 66.458z"/></svg></label></div></header><article><p class=meta>Last updated
Mar 8, 2023</p><ul class=tags></ul><aside class=mainTOC><details><summary>Table of Contents</summary><nav id=TableOfContents><ol><li><a href=#definition--risk-factors>Definition & Risk Factors</a></li><li><a href=#pathophysiology-and-clinical-features>Pathophysiology and Clinical Features</a><ol><li><a href=#skin>Skin</a></li><li><a href=#joint>Joint</a></li><li><a href=#renal>Renal</a></li><li><a href=#hematologic>Hematologic</a></li></ol></li><li><a href=#classification-diagnosis>Classification (Diagnosis)</a><ol><li><a href=#monitoring>Monitoring</a></li></ol></li><li><a href=#general-sle-management>General SLE Management</a><ol><li><a href=#non-pharmacological-management>Non-pharmacological management</a></li><li><a href=#pharmacological-management>Pharmacological management</a></li></ol></li><li><a href=#lupus-nephritis-management>Lupus Nephritis Management</a></li><li><a href=#pharmacotherapy-‡πÅ‡∏ö‡∏ö‡πÄ‡∏ô‡∏ô-‡πÜ>Pharmacotherapy ‡πÅ‡∏ö‡∏ö‡πÄ‡∏ô‡πâ‡∏ô ‡πÜ</a></li><li><a href=#‡∏Å‡∏≤‡∏£‡∏£‡∏Å‡∏©‡∏≤‡∏≠‡∏ô-‡πÜ>‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏≠‡∏∑‡πà‡∏ô ‡πÜ</a></li><li><a href=#antiphospholipid-syndrome-aps>Antiphospholipid syndrome (APS)</a><ol><li></li></ol></li><li><a href=#pregnancy-and-contraception>Pregnancy and Contraception</a></li><li><a href=#drug-induced-lupus>Drug Induced Lupus</a></li></ol></nav></details></aside><a href=#definition--risk-factors><h2 id=definition--risk-factors><span class=hanchor arialabel=Anchor># </span>Definition & Risk Factors</h2></a><ul><li>‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ autoimmune ‡∏ó‡∏±‡πâ‡∏á CMI, HMI</li><li>‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á > ‡∏ú‡∏π‡πâ‡∏ä‡∏≤‡∏¢</li><li>‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô ‡πÄ‡∏ä‡πà‡∏ô estrogen</li><li>‡πÄ‡∏õ‡πá‡∏ô‡πÉ‡∏ô‡∏ß‡∏±‡∏¢‡πÄ‡∏à‡∏£‡∏¥‡∏ç‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡πå‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤</li><li>‡∏û‡∏±‡∏ô‡∏ò‡∏∏‡∏Å‡∏£‡∏£‡∏°‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á</li><li>‡∏™‡∏¥‡πà‡∏á‡πÅ‡∏ß‡∏î‡∏•‡πâ‡∏≠‡∏° ‡∏™‡∏≤‡∏£‡∏ó‡∏µ‡πà‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏Å‡πá‡∏°‡∏µ‡∏™‡πà‡∏ß‡∏ô‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á<ul><li>‡∏Å‡∏≤‡∏£‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡πÑ‡∏õ‡∏ô‡∏≤‡∏ô ‡πÜ ‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô self-tolerance ‡∏Ç‡∏≠‡∏á innate immunity ‡∏•‡∏î‡∏•‡∏á ‡∏ó‡∏≥‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏î auto-antibodies production</li></ul></li><li>‡∏Å‡∏≤‡∏£‡∏ï‡∏¥‡∏î‡πÄ‡∏ä‡∏∑‡πâ‡∏≠ EBV</li><li>UV</li></ul><a href=#pathophysiology-and-clinical-features><h2 id=pathophysiology-and-clinical-features><span class=hanchor arialabel=Anchor># </span>Pathophysiology and Clinical Features</h2></a><ul><li>‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á‡∏†‡∏π‡∏°‡∏¥‡∏Ñ‡∏∏‡πâ‡∏°‡∏Å‡∏±‡∏ô‡∏ï‡πà‡∏≠ nucleus ‡∏Ç‡∏≠‡∏á‡πÄ‡∏ã‡∏•‡∏•‡πå (autoantibody) ‡πÄ‡∏ä‡πà‡∏ô <strong>anti-dsDNA</strong> ‡πÅ‡∏•‡∏∞ <strong>anti-Sm</strong></li><li>immune complex ‡∏ó‡∏µ‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÑ‡∏õ‡∏ï‡∏Å‡∏ï‡∏∞‡∏Å‡∏≠‡∏ô‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ï‡πà‡∏≤‡∏á ‡πÜ ‡πÄ‡∏Å‡∏¥‡∏î‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ï‡∏≤‡∏°‡∏≠‡∏ß‡∏±‡∏¢‡∏ß‡∏∞‡∏ô‡∏±‡πâ‡∏ô ‡πÜ</li><li>‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏û‡∏ö‡πÑ‡∏î‡πâ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏à‡∏∞‡πÄ‡∏õ‡πá‡∏ô‡∏ó‡∏≤‡∏á‡∏Ç‡πâ‡∏≠‡πÅ‡∏•‡∏∞‡∏ú‡∏¥‡∏ß‡∏´‡∏ô‡∏±‡∏á (90%) ‡∏ã‡∏∂‡πà‡∏á‡∏´‡∏≤‡∏Å‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏µ‡πÅ‡∏Ñ‡πà 2 ‡∏£‡∏∞‡∏ö‡∏ö‡∏ô‡∏µ‡πâ prognosis ‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏î‡∏µ ‡πÉ‡∏ô‡∏ó‡∏≤‡∏á‡∏ï‡∏£‡∏á‡∏Å‡∏±‡∏ô‡∏Ç‡πâ‡∏≤‡∏° ‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏£‡∏∞‡∏ö‡∏ö‡∏≠‡∏∑‡πà‡∏ô ‡πÜ ‡πÄ‡∏ä‡πà‡∏ô CNS ‡∏´‡∏£‡∏∑‡∏≠ renal ‡∏°‡∏±‡∏Å‡∏à‡∏∞ prognosis ‡∏´‡πà‡∏ß‡∏¢‡πÅ‡∏ï‡∏Å</li></ul><a href=#skin><h3 id=skin><span class=hanchor arialabel=Anchor># </span>Skin</h3></a><ul><li>‡∏à‡∏∞‡∏°‡∏µ‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÄ‡∏à‡∏≤‡∏∞‡∏à‡∏á‡∏Å‡∏±‡∏ö‡πÇ‡∏£‡∏Ñ</li><li>acute LE<ul><li>malar rash or butterfly rash : ‡πÄ‡∏õ‡πâ‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ó‡∏µ‡πà‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ö‡∏£‡∏¥‡πÄ‡∏ß‡∏ì nasolabial folds</li><li>bullous LE ‡πÄ‡∏õ‡πá‡∏ô‡∏ú‡∏∑‡πà‡∏ô‡∏ï‡∏∏‡πà‡∏°‡∏ô‡πâ‡∏≥</li></ul></li><li>subacute LE<ul><li>psoriatic like, ‡∏ß‡∏á ‡πÜ ‡∏Ç‡∏≠‡∏ö‡πÅ‡∏î‡∏á ‡∏Å‡∏•‡∏≤‡∏á‡∏Ç‡∏≤‡∏ß</li></ul></li><li>chronic LE<ul><li>discoid rash<ul><li>‡πÄ‡∏õ‡πá‡∏ô‡πÄ‡∏´‡∏°‡∏∑‡∏≠‡∏ô‡∏™‡πÄ‡∏Å‡πá‡∏î‡πÄ‡∏á‡∏¥‡∏ô‡πÄ‡∏•‡πá‡∏Å ‡πÜ</li><li>‡∏°‡∏µ‡∏™‡πÄ‡∏Å‡πá‡∏î</li><li>‡∏û‡∏ö hair scaring ‡∏à‡∏≤‡∏Å‡∏Å‡∏≤‡∏£‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≠‡∏°‡πÑ‡∏Ç‡∏°‡∏±‡∏ô‡πÅ‡∏•‡∏∞‡∏£‡∏π‡∏Ç‡∏∏‡∏°‡∏Ç‡∏ô‡∏ñ‡∏π‡∏Å‡∏ó‡∏≥‡∏ó‡∏•‡∏≤‡∏¢‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÄ‡∏°‡πá‡∏î‡πÄ‡∏•‡∏∑‡∏≠‡∏î‡∏Ç‡∏≤‡∏ß</li></ul></li></ul></li></ul><a href=#joint><h3 id=joint><span class=hanchor arialabel=Anchor># </span>Joint</h3></a><ul><li>arthritis ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤ 2 ‡∏Ç‡πâ‡∏≠ ‡∏Ñ‡∏•‡πâ‡∏≤‡∏¢ RA</li><li>+- ‡∏õ‡∏ß‡∏î ‡∏Å‡∏≤‡∏£‡∏î‡∏≥‡πÄ‡∏ô‡∏¥‡∏ô‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡πÄ‡∏£‡∏∑‡πâ‡∏≠‡∏£‡∏±‡∏á</li><li><strong>‡∏ú‡∏• film ‡∏à‡∏∞‡πÑ‡∏°‡πà‡πÄ‡∏à‡∏≠ erosion!! ‡∏ï‡πà‡∏≤‡∏á‡∏à‡∏≤‡∏Å <a href=/notes/21-OA rel=noopener class=internal-link data-src=/notes/21-OA>21 - OA</a> ‡πÅ‡∏•‡∏∞ <a href=/notes/22-RA rel=noopener class=internal-link data-src=/notes/22-RA>22 - RA</a></strong></li></ul><a href=#renal><h3 id=renal><span class=hanchor arialabel=Anchor># </span>Renal</h3></a><ul><li>Lupus nephritis ‡∏û‡∏ö‡πÉ‡∏ô‡πÄ‡∏≠‡πÄ‡∏ä‡∏µ‡∏¢‡πÄ‡∏¢‡∏≠‡∏∞‡∏™‡∏∏‡∏î</li><li>‡∏°‡∏±‡∏Å‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô 3-5 ‡∏õ‡∏µ‡πÅ‡∏£‡∏Å‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ</li><li>‡∏°‡∏±‡∏Å‡∏û‡∏ö‡πÇ‡∏õ‡∏£‡∏ï‡∏µ‡∏ô‡∏£‡∏±‡πà‡∏ß ‡πÅ‡∏°‡πâ‡∏Ñ‡∏∏‡∏° BP ‡πÑ‡∏î‡πâ‡πÅ‡∏•‡πâ‡∏ß‡∏Å‡πá‡∏ï‡∏≤‡∏°</li><li>‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏á‡∏≤‡∏ô‡πÑ‡∏ï‡∏•‡∏î‡πÄ‡∏£‡πá‡∏ß‡∏Å‡∏ß‡πà‡∏≤ AKI</li><li>‡∏Ñ‡∏ß‡∏£‡∏ó‡∏≥ biopsy ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏µ‡∏Å‡∏≤‡∏£ classify ‡∏ï‡∏≤‡∏° histology<ul><li>Class III , Class IV ‡∏Ñ‡πà‡∏≠‡∏ô‡∏Ç‡πâ‡∏≤‡∏á active</li><li>Class V cell ‡∏ï‡∏≤‡∏¢</li><li>Class VI ‡πÑ‡∏°‡πà‡πÄ‡∏´‡∏•‡∏∑‡∏≠‡πÑ‡∏£‡πÅ‡∏•‡πâ‡∏ß</li></ul></li><li>‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏ï‡∏≤‡∏° <strong>KDIGO2021</strong></li><li>‡πÄ‡∏Å‡∏¥‡∏î‡∏à‡∏≤‡∏Å immune complex ‡πÑ‡∏õ deposit ‡πÅ‡∏ï‡πà organ ‡∏≠‡∏∑‡πà‡∏ô‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡πÅ‡∏õ‡∏•‡∏ß‡πà‡∏≤‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏≤‡∏à‡∏≤‡∏Å immune complex!</li></ul><a href=#hematologic><h3 id=hematologic><span class=hanchor arialabel=Anchor># </span>Hematologic</h3></a><ul><li>‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î autolytic hemolysis ‡∏ú‡∏¥‡∏î‡∏õ‡∏Å‡∏ï‡∏¥‡∏ó‡∏±‡πâ‡∏á wbc, rbc ‡πÅ‡∏•‡∏∞ platelet (leukopenia, lymphopenia, thrombocytopenia)</li><li>‡∏ñ‡πâ‡∏≤ autoimmune hemolytic anema ‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏û‡∏ö‡∏ú‡∏• coomb&rsquo;s test positive<ul><li>coomb test ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡∏ß‡πà‡∏≤‡∏°‡∏µ anti-rbc antibody ‡∏≠‡∏¢‡∏π‡πà‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà / ‡πÄ‡∏õ‡πá‡∏ô‡∏Å‡∏≤‡∏£‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡∏ß‡πà‡∏≤‡∏°‡∏µ antibody ‡πÄ‡∏Å‡∏≤‡∏∞‡∏≠‡∏¢‡∏π‡πà‡∏ö‡∏ô rbc ‡∏´‡∏£‡∏∑‡∏≠‡πÑ‡∏°‡πà</li></ul></li><li>‡∏£‡∏∞‡∏ß‡∏±‡∏á‡∏™‡∏±‡∏ö‡∏™‡∏ô‡∏Å‡∏≤‡∏£‡∏ã‡∏µ‡∏î‡∏à‡∏≤‡∏Å‡∏¢‡∏≤‡∏Å‡∏î‡∏†‡∏π‡∏°‡∏¥</li><li>SLE ‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏ó‡∏≤‡∏á‡∏î‡πâ‡∏≤‡∏ô metabolic ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡πÄ‡∏õ‡πá‡∏ô major risk ‡∏Ç‡∏≠‡∏á‡πÇ‡∏£‡∏Ñ‡∏ó‡∏≤‡∏á CVD</li></ul><a href=#classification-diagnosis><h2 id=classification-diagnosis><span class=hanchor arialabel=Anchor># </span>Classification (Diagnosis)</h2></a><ul><li>‡πÑ‡∏°‡πà‡∏°‡∏µ‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡∏ß‡∏¥‡∏ô‡∏¥‡∏à‡∏â‡∏±‡∏¢ ‡πÄ)‡πâ‡∏ô‡πÅ‡∏Ñ‡πà‡πÄ‡∏Å‡∏ì‡∏ë‡πå‡πÉ‡∏ô‡∏Å‡∏≤‡∏£ classification<ul><li>ACR</li><li>2012 SLICC</li><li><strong>2019 EULAR/ACR</strong> ‡πÉ‡∏´‡∏°‡πà‡∏™‡∏∏‡∏î ‡∏Ç‡πâ‡∏≠‡πÄ‡∏™‡∏µ‡∏¢‡∏Ñ‡∏∑‡∏≠‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡πÅ‡∏Ñ‡πà‡πÉ‡∏ô US&EU ‡πÅ‡∏•‡∏∞‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ‡∏ó‡∏î‡∏™‡∏≠‡∏ö‡πÉ‡∏ô‡πÄ‡∏î‡πá‡∏Å</li></ul></li><li>EULAR/ACR entry criteria<ul><li>ANA positive at >= 1:80 titer<ul><li>pos -> additive criteria ‡πÇ‡∏î‡∏¢‡∏ï‡πâ‡∏≠‡∏á >= 10 ‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡∏ï‡πâ‡∏≠‡∏á‡∏°‡∏µ‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏ó‡∏≤‡∏á‡∏ù‡∏±‡πà‡∏á clinic ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 1 ‡∏Ç‡πâ‡∏≠ ‡∏Å‡πá‡∏à‡∏∞‡∏ñ‡∏∑‡∏≠‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô classified SLE</li><li>neg -> ‡πÑ‡∏°‡πà‡∏ï‡πâ‡∏≠‡∏á‡∏õ‡∏£‡∏∞‡πÄ‡∏°‡∏¥‡∏ô‡∏ï‡πà‡∏≠</li><li>note: ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡∏Ñ‡∏∞‡πÅ‡∏ô‡∏ô‡πÑ‡∏°‡πà‡∏ñ‡∏∂‡∏á 10 ‡πÅ‡∏ï‡πà‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡πÄ‡∏Ç‡πâ‡∏≤‡πÑ‡∏î‡πâ ‡∏´‡∏£‡∏∑‡∏≠ ANA neg ‡πÅ‡∏ï‡πà entry criterion ‡∏≠‡∏∑‡πà‡∏ô‡πÄ‡∏Ç‡πâ‡∏≤ ‡∏Å‡πá‡∏à‡∏∞‡∏ñ‡∏∑‡∏≠‡∏ß‡πà‡∏≤‡πÄ‡∏õ‡πá‡∏ô clinical SLE</li></ul></li></ul></li></ul><a href=#monitoring><h3 id=monitoring><span class=hanchor arialabel=Anchor># </span>Monitoring</h3></a><ul><li>SLEDIA-2K<ul><li>Remission = 0</li><li>Low Activity = 1-4</li></ul></li></ul><a href=#general-sle-management><h2 id=general-sle-management><span class=hanchor arialabel=Anchor># </span>General SLE Management</h2></a><a href=#non-pharmacological-management><h3 id=non-pharmacological-management><span class=hanchor arialabel=Anchor># </span>Non-pharmacological management</h3></a><ul><li><a href=#skin rel=noopener class=internal-link data-src></a> -> ‡∏Ñ‡∏£‡∏µ‡∏°‡∏Å‡∏±‡∏ô‡πÅ‡∏î‡∏î</li><li><a href=#joint rel=noopener class=internal-link data-src></a> -> ‡∏ó‡∏≥ rehab</li><li>‡∏ô‡∏≠‡∏ô‡∏û‡∏±‡∏Å‡∏ú‡πà‡∏≠‡∏ô‡πÉ‡∏´‡πâ‡πÄ‡∏û‡∏µ‡∏¢‡∏á‡∏û‡∏≠ ‡∏£‡∏∞‡∏ß‡∏±‡∏á‡πÄ‡∏£‡∏¥‡∏°‡∏ö‡∏∏‡∏Å‡∏à‡πâ‡∏≤</li><li><strong>‡∏Å‡∏≤‡∏£‡∏ß‡∏≤‡∏á‡πÅ‡∏ú‡∏ô‡∏ï‡∏±‡πâ‡∏á‡∏Ñ‡∏£‡∏£‡∏†‡πå‡∏™‡∏≥‡∏Ñ‡∏±‡∏ç‡∏°‡∏≤‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å‡∏Å</strong></li></ul><a href=#pharmacological-management><h3 id=pharmacological-management><span class=hanchor arialabel=Anchor># </span>Pharmacological management</h3></a><p><a class="internal-link broken">500</a>
<a class="internal-link broken">Pasted image 20230308154054.png</a>
<a class="internal-link broken">Pasted image 20230308154100.png</a></p><a href=#lupus-nephritis-management><h2 id=lupus-nephritis-management><span class=hanchor arialabel=Anchor># </span>Lupus Nephritis Management</h2></a><ul><li>ACEi, ARB to reduce proteinuria</li><li>‡∏Ñ‡∏∏‡∏° BP ‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÄ‡∏Å‡∏¥‡∏ô 130/80 mmHg</li><li>‡∏°‡∏±‡∏Å‡∏à‡∏∞‡∏£‡∏±‡∏Å‡∏©‡∏≤ Class III ‡πÅ‡∏•‡∏∞ Class IV<ul><li><a class="internal-link broken">475</a></li><li><a class="internal-link broken">500</a></li><li>Euro-lupus regimen : IV CY 500 every 2 weeks for six dose<ul><li>response well in white and asian patient</li></ul></li><li>NIH Regimen : IV CY 500-1000 mg/m2 BSA once a month for six dose<ul><li>response well in african, american, hispanic</li></ul></li><li>‡∏´‡∏•‡∏±‡∏á Maintenance ‡πÉ‡∏´‡πâ tape prednisolone ‡∏•‡∏á‡∏°‡∏≤‡πÉ‡∏´‡πâ‡πÑ‡∏î‡πâ</li></ul></li><li>Class V<ul><li>‡∏ñ‡πâ‡∏≤‡∏™‡∏π‡∏ç‡πÄ‡∏™‡∏µ‡∏¢‡πÑ‡∏ï‡πÑ‡∏õ‡∏ö‡∏≤‡∏á‡∏™‡πà‡∏ß‡∏ô‡πÅ‡∏•‡πâ‡∏ß ‡πÉ‡∏´‡πâ‡∏ä‡∏±‡πà‡∏á risk and benefit ‡πÉ‡∏´‡πâ‡∏î‡∏µ‡∏ß‡πà‡∏≤‡∏Ñ‡∏ß‡∏£‡πÄ‡∏£‡∏¥‡πà‡∏° immunsupressive ‡∏°‡∏±‡πâ‡∏¢</li><li>‡πÄ‡∏ô‡πâ‡∏ô‡∏Å‡∏≤‡∏£‡∏Ñ‡∏∏‡∏° level of proteinuria and complication ‡∏ó‡∏µ‡πà‡∏≠‡∏≤‡∏à‡∏ï‡∏≤‡∏°‡∏°‡∏≤</li></ul></li></ul><a href=#pharmacotherapy-‡πÅ‡∏ö‡∏ö‡πÄ‡∏ô‡∏ô-‡πÜ><h2 id=pharmacotherapy-‡πÅ‡∏ö‡∏ö‡πÄ‡∏ô‡∏ô-‡πÜ><span class=hanchor arialabel=Anchor># </span>Pharmacotherapy ‡πÅ‡∏ö‡∏ö‡πÄ‡∏ô‡πâ‡∏ô ‡πÜ</h2></a><ul><li><a class="internal-link broken">CC1 - MCQ</a></li><li>‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ Corticosteroid ‡πÉ‡∏ô SLE ‡∏°‡∏µ‡∏´‡∏•‡∏≤‡∏¢‡πÅ‡∏ö‡∏ö<ul><li>Pulse GC : >= 250 mg PDNeq/day ‡πÉ‡∏ä‡πâ‡∏™‡∏≥‡∏´‡∏£‡∏±‡∏ö‡πÄ‡∏Ñ‡∏™ life threatening ‡πÉ‡∏´‡πâ‡∏£‡∏∞‡∏ß‡∏±‡∏á fluid overload, neuro symptoms, uncontrolled bp, cardiac arhythmia ‡∏°‡∏±‡∏Å‡πÉ‡∏ä‡πâ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏î 2-3 ‡∏ß‡∏±‡∏ô</li><li>Moderate Dose : >7.5-30 PDNeq/day IV or po ‡∏°‡∏±‡∏Å‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤ flare</li><li>Low Dose GCs: &lt;= 7.5 PDNeq/day po</li><li>Alternate-day : ‡πÉ‡∏ä‡πâ tape seteroid ‡∏°‡∏≤‡∏Å‡∏Å‡∏ß‡πà‡∏≤</li></ul></li><li>‡∏≠‡∏¢‡πà‡∏≤‡∏•‡∏∑‡∏° ADR steroid<ul><li>osteonecrosis ‡∏≠‡∏±‡∏ô‡∏ï‡∏£‡∏≤‡∏¢!</li><li>osteoporosis when long-term use -> fracture</li><li>adrenal insuff -> tired</li><li>psychosis</li></ul></li><li>Contraindication ‡πÉ‡∏ô‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ Pulse<ul><li>Infection</li><li>Pregnancy and Lactation</li><li>Current peptic ulcer disease</li><li>Glaucoma</li><li>Badly controlled HTN or DM</li></ul></li><li>Immunosupressive agents<ul><li>‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà serious, severe</li><li>HCQ or CQ ‡πÉ‡∏ä‡πâ‡∏•‡∏î constitutional symptoms ‡∏ô‡∏¥‡∏¢‡∏°‡πÉ‡∏ä‡πâ‡∏£‡πà‡∏ß‡∏°‡∏Å‡∏±‡∏ö‡∏¢‡∏≤‡∏≠‡∏∑‡πà‡∏ô</li></ul></li></ul><a href=#‡∏Å‡∏≤‡∏£‡∏£‡∏Å‡∏©‡∏≤‡∏≠‡∏ô-‡πÜ><h2 id=‡∏Å‡∏≤‡∏£‡∏£‡∏Å‡∏©‡∏≤‡∏≠‡∏ô-‡πÜ><span class=hanchor arialabel=Anchor># </span>‡∏Å‡∏≤‡∏£‡∏£‡∏±‡∏Å‡∏©‡∏≤‡∏≠‡∏∑‡πà‡∏ô ‡πÜ</h2></a><ul><li>Plasmaexchange (Plsamapheresis) ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡∏≥‡∏à‡∏∞‡πÉ‡∏™‡πà albumin ‡πÑ‡∏õ‡∏î‡πâ‡∏ß‡∏¢, ‡∏£‡∏∞‡∏ß‡∏±‡∏á hypocalcemia</li><li>IVIG ‡∏ä‡∏∞‡∏•‡∏≠‡∏Å‡∏≤‡∏£‡∏ó‡∏≥‡∏•‡∏≤‡∏¢‡∏Ç‡∏≠‡∏á antibody coated autologous red blood cell ‡πÅ‡∏•‡∏∞ ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏™‡∏£‡πâ‡∏≤‡∏á cytokine & anti-idiotypic antibody ‡∏à‡∏∞‡πÉ‡∏ä‡πâ‡πÉ‡∏ô‡πÄ‡∏Ñ‡∏™‡∏ó‡∏µ‡πà severe life-threatening ‡∏ó‡∏µ‡πà‡πÉ‡∏ä‡πâ steroid or immunosupressive ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ<ul><li>‡πÄ‡∏õ‡πá‡∏ô‡πÅ‡∏Ñ‡πà cas-report</li></ul></li><li>Vitamin D esp ‡∏Ñ‡∏ô‡∏ú‡∏¥‡∏ß‡∏î‡∏≥ ‡πÅ‡∏•‡∏∞ vit d def ‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö‡∏Å‡∏≤‡∏£‡∏°‡∏µ cytokine/allergy ‡∏ó‡∏µ‡πà high<ul><li>‡∏Ñ‡∏ß‡∏£‡πÄ‡∏à‡∏≤‡∏∞ baseline 25(OH) vit D ‡πÄ‡∏õ‡πá‡∏ô baseline ‡πÇ‡∏î‡∏¢‡∏Ñ‡∏ß‡∏£ > 30 ng/mL</li><li>‡∏≠‡∏≤‡∏à‡πÉ‡∏´‡πâ‡∏£‡∏±‡∏ö‡∏õ‡∏£‡∏∞‡∏ó‡∏≤‡∏ô vit D 30-50 ug (1000-2000 IU) ‡πÇ‡∏î‡∏¢‡πÄ‡∏â‡∏û‡∏≤‡∏∞‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà‡∏Å‡∏¥‡∏ô steroid</li><li>‡πÉ‡∏ô‡πÑ‡∏ó‡∏¢‡∏°‡∏±‡∏Å‡πÉ‡∏ä‡πâ D2 ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏ñ‡∏π‡∏Å</li><li>D2 ‡∏ï‡πâ‡∏≠‡∏á‡∏ú‡πà‡∏≤‡∏ô‡∏ï‡∏±‡∏ö (‡πÄ‡∏ï‡∏¥‡∏°25-OH)</li><li>D3 ‡∏ï‡πâ‡∏≠‡∏á‡∏ú‡πà‡∏≤‡∏ô‡πÑ‡∏ï (‡πÄ‡∏ï‡∏¥‡∏° 1-OH)</li><li>‡∏õ‡∏Å‡∏ï‡∏¥‡∏à‡∏∞ ‡∏ï‡∏±‡∏ö ‡πÄ‡∏ï‡∏¥‡∏° 25-OH -> ‡πÑ‡∏ï ‡πÄ‡∏ï‡∏¥‡∏° 1 OH</li></ul></li></ul><a href=#antiphospholipid-syndrome-aps><h2 id=antiphospholipid-syndrome-aps><span class=hanchor arialabel=Anchor># </span>Antiphospholipid syndrome (APS)</h2></a><ul><li>‡∏à‡∏∞‡∏°‡∏≠‡∏á‡πÄ‡∏õ‡πá‡∏ô‡πÇ‡∏£‡∏Ñ‡∏´‡∏£‡∏∑‡∏≠ complication ‡∏Å‡πá‡πÑ‡∏î‡πâ</li><li>‡∏°‡∏±‡∏Å‡∏à‡∏∞‡πÉ‡∏ä‡πâ LDA ‡∏´‡∏£‡∏∑‡∏≠ anticoagulants ‡πÄ‡∏õ‡πá‡∏ô‡∏´‡∏•‡∏±‡∏Å</li><li>‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ HCQ or statin (‡πÅ‡∏ï‡πà‡∏õ‡∏Å‡∏ï‡∏¥‡∏Ñ‡∏ô‡∏ó‡∏µ‡πà SLE ‡∏à‡∏∞‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö HCQ ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß)</li></ul><a href=#‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏ß‡πÑ‡∏õ><h4 id=‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏ß‡πÑ‡∏õ><span class=hanchor arialabel=Anchor># </span>‡πÉ‡∏ô‡∏Ñ‡∏ô‡∏ó‡∏±‡πà‡∏ß‡πÑ‡∏õ</h4></a><ul><li>‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE ‡πÑ‡∏°‡πà‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô‡∏ï‡πâ‡∏≠‡∏á‡∏ï‡∏£‡∏ß‡∏à aPL (antiphospholipidantibodies) ‡∏ó‡∏∏‡∏Å‡∏£‡∏≤‡∏¢</li><li>asymptomatic aPL carriers -> ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ prophylaxis LDA 75-100 mg</li><li>‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE ‡∏ñ‡πâ‡∏≤ high risk of aPL profile ‡πÉ‡∏´‡πâ prophylaxis ‡∏î‡πâ‡∏ß‡∏¢ LDA</li><li>‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE ‡∏ñ‡πâ‡∏≤ low risk of aPL profile <strong>‡∏≠‡∏≤‡∏à</strong>‡πÉ‡∏´‡πâ prophylaxis ‡∏î‡πâ‡∏ß‡∏¢ LDA</li></ul><a href=#‡πÉ‡∏ô‡∏ú‡∏´‡∏ç‡∏á‡∏ó-aps-‡πÅ‡∏•‡∏∞‡∏ó‡∏≠‡∏á><h4 id=‡πÉ‡∏ô‡∏ú‡∏´‡∏ç‡∏á‡∏ó-aps-‡πÅ‡∏•‡∏∞‡∏ó‡∏≠‡∏á><span class=hanchor arialabel=Anchor># </span>‡πÉ‡∏ô‡∏ú‡∏π‡πâ‡∏´‡∏ç‡∏¥‡∏á‡∏ó‡∏µ‡πà APS ‡πÅ‡∏•‡∏∞‡∏ó‡πâ‡∏≠‡∏á</h4></a><ul><li>‡∏ñ‡πâ‡∏≤ high-risk aPL ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ LDA ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡πâ‡∏≠‡∏á</li><li>‡∏ñ‡πâ‡∏≤‡πÄ‡∏Ñ‡∏¢‡∏°‡∏µ‡∏õ‡∏£‡∏∞‡∏ß‡∏±‡∏ï‡∏¥ APS<ul><li>‡πÅ‡∏ó‡πâ‡∏á GA &lt; 10 wk -> ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥ LDA and heparin ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡πâ‡∏≠‡∏á</li><li>‡∏Ñ‡∏•‡∏≠‡∏î‡∏Å‡πà‡∏≠‡∏ô‡∏Å‡∏≥‡∏´‡∏ô‡∏î (&lt; 34 wks) -> ‡πÅ‡∏ô‡∏∞‡∏ô‡∏≥‡πÉ‡∏´‡πâ LDA and heparin ‡∏£‡∏∞‡∏´‡∏ß‡πà‡∏≤‡∏á‡∏ó‡πâ‡∏≠‡∏á ‡πÅ‡∏ï‡πà‡πÉ‡∏´‡πâ‡∏î‡∏π risk ‡∏≠‡∏∑‡πà‡∏ô‡∏£‡πà‡∏ß‡∏°‡∏î‡πâ‡∏ß‡∏¢</li><li>‡∏´‡∏•‡∏±‡∏á‡∏Ñ‡∏•‡∏≠‡∏î ‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å‡πÉ‡∏ä‡πâ heparin ‡∏õ‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ô‡∏°‡∏≤‡∏Å‡πà‡∏≠‡∏ô ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 6 ‡∏™‡∏±‡∏õ‡∏î‡∏≤‡∏´‡πå‡∏´‡∏•‡∏±‡∏á‡∏Ñ‡∏•‡∏≠‡∏î</li></ul></li><li>Dose<ul><li>heparin 5000 u sc bid</li><li>LMWH 1 mg/kg/day</li></ul></li></ul><a href=#pregnancy-and-contraception><h2 id=pregnancy-and-contraception><span class=hanchor arialabel=Anchor># </span>Pregnancy and Contraception</h2></a><ul><li>cyclophosphamide 18-23 cumulative gram dose ‡∏≠‡∏≤‡∏à‡∏ó‡∏≥‡πÉ‡∏´‡πâ ovarian insufficiency</li><li>‡∏Ñ‡∏∏‡∏°‡∏Å‡∏≥‡πÄ‡∏ô‡∏¥‡∏î‡∏î‡πâ‡∏ß‡∏¢‡∏¢‡∏≤‡∏Æ‡∏≠‡∏£‡πå‡πÇ‡∏°‡∏ô‡∏ó‡∏µ‡πà‡∏°‡∏µ estrogen ‡πÑ‡∏°‡πà‡πÑ‡∏î‡πâ ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ POP ‡πÅ‡∏ï‡πà‡∏ñ‡πâ‡∏≤‡∏ï‡∏£‡∏ß‡∏à‡πÅ‡∏•‡πâ‡∏ß‡πÑ‡∏°‡πà‡∏û‡∏ö antiphospholipid antibodies ‡∏Å‡πá‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ ‡πÅ‡∏ï‡πà‡πÉ‡∏ä‡πâ‡πÇ‡∏î‡∏™‡∏ô‡πâ‡∏≠‡∏¢</li><li>‡∏ñ‡πâ‡∏≤‡∏´‡∏≤‡∏Å antiphospholipid antibodies positive ‡∏´‡πâ‡∏≤‡∏°‡πÉ‡∏ä‡πâ estrogen ‡πÄ‡∏û‡∏£‡∏≤‡∏∞ thrombosis risk ‡∏à‡∏∞‡πÄ‡∏û‡∏¥‡πà‡∏°‡πÑ‡∏î‡πâ ‡πÅ‡∏•‡∏∞ SLE ‡∏à‡∏∞‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö‡πÑ‡∏î‡πâ<ul><li>‡πÉ‡∏ä‡πâ pop, copper iud (adr ‡πÄ‡∏¢‡∏≠‡∏∞‡∏Å‡∏ß‡πà‡∏≤) ‡∏´‡∏£‡∏∑‡∏≠ progestin iud ‡πÅ‡∏ó‡∏ô</li></ul></li><li>‡∏Å‡∏≤‡∏£‡∏ó‡πâ‡∏≠‡∏á‡∏à‡∏∞‡πÄ‡∏Å‡∏¥‡∏î‡∏ú‡∏•‡πÄ‡∏™‡∏µ‡∏¢‡∏≠‡∏∞‡πÑ‡∏£‡∏ö‡πâ‡∏≤‡∏á‡πÉ‡∏ô‡∏Ñ‡∏ô‡πÑ‡∏Ç‡πâ SLE<ul><li>pre-eclampsia<ul><li>‡∏•‡∏î‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ LDA 16 wks ‡∏Å‡πà‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á ‡∏´‡∏£‡∏∑‡∏≠ HCQ ‡∏ï‡∏•‡∏≠‡∏î‡πÄ‡∏ß‡∏•‡∏≤‡∏ó‡πâ‡∏≠‡∏á</li></ul></li><li>congenital heart block<ul><li>‡∏ñ‡πâ‡∏≤‡πÅ‡∏°‡πà‡∏°‡∏µ anti-RO/SSA or anti-LA/SSB ‡∏•‡∏π‡∏Å‡∏à‡∏∞‡πÄ‡∏™‡∏µ‡πà‡∏¢‡∏á‡πÄ‡∏Å‡∏¥‡∏î‡∏°‡∏≤‡∏î‡πâ‡∏ß‡∏¢‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏á‡∏´‡∏±‡∏ß‡πÉ‡∏à ‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡∏•‡∏î‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ HCQ</li></ul></li><li>miscarriages</li></ul></li><li>‡∏Ñ‡∏ß‡∏£‡∏ó‡πâ‡∏≠‡∏á‡∏°‡∏±‡πâ‡∏¢<ul><li>‡πÇ‡∏£‡∏Ñ‡∏ô‡∏¥‡πà‡∏á ‡πÑ‡∏°‡πà‡∏°‡∏µ autoabs -> low risk</li><li>‡πÇ‡∏£‡∏Ñ‡∏ô‡∏¥‡πà‡∏á ‡∏°‡∏µ autoabs -> intermediate risk ‡πÉ‡∏´‡πâ‡∏£‡∏∞‡∏ß‡∏±‡∏á</li><li>‡πÇ‡∏£‡∏Ñ‡πÑ‡∏°‡πà‡∏ô‡∏¥‡πà‡∏á ‡∏°‡∏µ autoabs ‡πÅ‡∏•‡∏∞ irreversible damage -> ‡πÑ‡∏°‡πà‡∏Ñ‡∏ß‡∏£‡∏ó‡πâ‡∏≠‡∏á</li><li><strong>‡∏´‡∏≤‡∏Å‡∏û‡∏∂‡πà‡∏á flare ‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á 6 ‡πÄ‡∏î‡∏∑‡∏≠‡∏ô‡∏ó‡∏µ‡πà‡∏ú‡πà‡∏≤‡∏ô‡∏°‡∏≤ ‡∏´‡∏£‡∏∑‡∏≠‡∏°‡∏µ active lupus nephritis ‡∏´‡∏£‡∏∑‡∏≠ stsroke ‡πÑ‡∏°‡πà‡πÅ‡∏ô‡πà‡∏ô‡∏≥‡πÉ‡∏´‡πâ‡∏ó‡πâ‡∏≠‡∏á</strong> ‡∏î‡∏µ‡∏™‡∏∏‡∏î‡∏Ñ‡∏∑‡∏≠ inactive for 6 months ‡∏Å‡πà‡∏≠‡∏ô‡∏ó‡πâ‡∏≠‡∏á</li></ul></li><li>‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡∏ó‡πâ‡∏≠‡∏á ‡πÉ‡∏´‡πâ‡πÉ‡∏ä‡πâ HCQ ‡∏ï‡πà‡∏≠‡πÑ‡∏õ‡πÄ‡∏£‡∏∑‡πà‡∏≠‡∏¢ ‡πÜ ‡∏ï‡∏•‡∏≠‡∏î‡∏Å‡∏≤‡∏£‡∏ó‡πâ‡∏≠‡∏á</li><li>Teratogenic drugs<ul><li>MTX, thalidomide 1-3 month before</li><li>MMF 6 wks before</li><li>cyclophosphamide 3 mo before</li><li>leflunomide 2 yrs before (‡∏™‡∏≤‡∏°‡∏≤‡∏£‡∏ñ‡πÄ‡∏£‡πà‡∏á‡πÑ‡∏î‡πâ‡∏î‡πâ‡∏ß‡∏¢‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ cholestyramine)</li></ul></li><li>‡∏´‡∏≤‡∏Å‡∏ó‡πâ‡∏≠‡∏á‡πÅ‡∏•‡πâ‡∏ß‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏Å‡∏≥‡πÄ‡∏£‡∏¥‡∏ö<ul><li>AZA ‡πÑ‡∏°‡πà‡πÄ‡∏Å‡∏¥‡∏ô 2 mkday ‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÑ‡∏î‡πâ</li><li>cyclosporine, tacrolimus best alternative choices</li><li>VitD, calcium, folic ‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ‡∏≠‡∏¢‡∏π‡πà‡πÅ‡∏•‡πâ‡∏ß</li><li>‡∏ñ‡πâ‡∏≤‡∏à‡∏∞‡πÉ‡∏ä‡πâ steroid ‡∏Ñ‡∏ß‡∏£‡πÉ‡∏ä‡πâ‡∏ï‡πà‡∏≥‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î‡∏ó‡∏µ‡πà‡∏ï‡πà‡∏≥‡πÑ‡∏î‡πâ (7.5 or less)</li><li>‡∏ï‡∏≠‡∏ô‡∏à‡∏∞‡∏Ñ‡∏•‡∏≠‡∏î ‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á‡∏´‡∏ô‡∏±‡∏Å steroid ‡∏•‡∏î‡∏Å‡∏≤‡∏£‡∏≠‡∏±‡∏Å‡πÄ‡∏™‡∏ö‡πÑ‡∏°‡πà‡πÉ‡∏´‡πâ‡πÄ‡∏¢‡∏≠‡∏∞‡πÄ‡∏Å‡∏¥‡∏ô</li><li>‡∏≠‡∏≤‡∏à‡∏°‡∏µ‡∏Å‡∏≤‡∏£‡πÉ‡∏ä‡πâ fluorinated corticosteroid ‡πÄ‡∏ä‡πà‡∏ô dexamethasone, betamethasone ‡∏´‡∏≤‡∏Å‡∏ï‡πâ‡∏≠‡∏á‡∏Å‡∏≤‡∏£‡πÉ‡∏´‡πâ‡∏•‡∏π‡∏Å‡πÑ‡∏î‡πâ‡∏£‡∏±‡∏ö‡∏¢‡∏≤‡∏î‡πâ‡∏ß‡∏¢ ‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡∏°‡∏±‡∏ô‡∏ú‡πà‡∏≤‡∏ô placenta</li></ul></li><li>biologics no ‡∏Ç‡πâ‡∏≠‡∏°‡∏π‡∏•!<ul><li>certolizumab ‡∏î‡∏π safe ‡∏™‡∏∏‡∏î‡πÄ‡∏û‡∏£‡∏≤‡∏∞‡πÑ‡∏°‡πà‡∏°‡∏µ Fc chain</li><li>Rituximab ‡πÑ‡∏°‡πà‡∏Ñ‡∏ß‡∏£‡πÉ‡∏´‡πâ</li></ul></li><li>Cyclophosphamide damage male sperm ‡πÑ‡∏î‡πâ ‡∏î‡∏±‡∏á‡∏ô‡∏±‡πâ‡∏ô‡∏Ñ‡∏ß‡∏£‡∏´‡∏¢‡∏∏‡∏î‡∏≠‡∏¢‡πà‡∏≤‡∏á‡∏ô‡πâ‡∏≠‡∏¢ 12 wks</li></ul><a href=#drug-induced-lupus><h2 id=drug-induced-lupus><span class=hanchor arialabel=Anchor># </span>Drug Induced Lupus</h2></a><ul><li>proposed mech<ul><li>haptenization</li><li>macrophage uptake apoptotic or necrotic cells leading to accumulation of self-antigen</li><li>stimualation of NETs form cell death that let self-antigen stimulate autoreactive T or B cell</li><li>dysregulation of T cell</li></ul></li><li>no standard criteria</li><li>‡∏≠‡∏≤‡∏à‡πÄ‡∏à‡∏≠ anti-histone ‡∏´‡∏£‡∏∑‡∏≠ anti-ssDNA</li><li>‡∏≠‡∏≤‡∏Å‡∏≤‡∏£‡∏°‡∏±‡∏Å‡πÑ‡∏°‡πà‡∏£‡∏∏‡∏ô‡πÅ‡∏£‡∏á</li><li>positive lupus band test</li><li>sweet syndrome</li><li>High risk drugs<ul><li>Procainamide<ul><li><strong>‡πÄ‡∏î‡πà‡∏ô‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡∏õ‡∏≠‡∏î</strong> ‡πÅ‡∏•‡∏∞‡∏õ‡∏ß‡∏î‡πÑ‡∏Ç‡πâ</li><li>‡∏°‡∏±‡∏Å‡∏ó‡∏≥‡πÉ‡∏´‡πâ ANA positive</li></ul></li><li>Hydralazine<ul><li><strong>‡πÄ‡∏î‡πà‡∏ô‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡πÑ‡∏ï</strong> ‡πÅ‡∏•‡∏∞‡∏õ‡∏ß‡∏î‡πÑ‡∏Ç‡πâ</li><li>esp dose over 200 mg/day or cumulative ‡πÄ‡∏Å‡∏¥‡∏ô 100 g</li><li>‡πÄ‡∏à‡∏≠ ANA pos ‡∏ô‡πâ‡∏≠‡∏¢</li></ul></li></ul></li><li>Moderate risk<ul><li>minocycline</li><li>isoniazid</li><li>methyldopa</li><li>cbz</li><li>chlorpromazine</li></ul></li><li>drug induced subacute cutaneous<ul><li>‡πÄ‡∏Å‡∏µ‡πà‡∏¢‡∏ß‡∏Ç‡πâ‡∏≠‡∏á‡∏Å‡∏±‡∏ö terbinafine ‡πÅ‡∏•‡∏∞ TNF-alpha ‡∏°‡∏≤‡∏Å‡∏ó‡∏µ‡πà‡∏™‡∏∏‡∏î</li><li>‡∏≠‡∏≤‡∏à‡∏û‡∏ö positive ANA, anti-ro, anti-la ‡πÑ‡∏î‡πâ</li><li>‡∏≠‡∏≤‡∏à‡πÄ‡∏Å‡∏¥‡∏î‡πÉ‡∏ô‡∏ä‡πà‡∏ß‡∏á 1 ‡∏õ‡∏µ‡∏´‡∏•‡∏±‡∏á‡πÄ‡∏£‡∏¥‡πà‡∏°‡∏¢‡∏≤</li><li>‡∏°‡∏±‡∏Å‡πÄ‡∏Å‡∏¥‡∏î‡∏Å‡∏±‡∏ö‡∏Ñ‡∏ô‡πÅ‡∏Å‡πà</li></ul></li><li>chronic cutaenous lupus<ul><li>‡∏û‡∏ö‡πÄ‡∏à‡∏≠‡πÉ‡∏ô 5-FU</li></ul></li><li>management<ul><li>‡∏´‡∏¢‡∏∏‡∏î‡∏¢‡∏≤ ‡πÅ‡∏•‡∏∞‡∏à‡∏∞‡∏î‡∏µ‡∏Ç‡∏∂‡πâ‡∏ô‡πÉ‡∏ô 1 wks ‡πÅ‡∏•‡∏∞‡∏≠‡∏≤‡∏à‡πÉ‡∏ä‡πâ‡πÄ‡∏ß‡∏•‡∏≤ recover ‡∏ô‡∏≤‡∏ô‡∏ñ‡∏∂‡∏á 1 ‡∏õ‡∏µ</li><li>low-dose pred ‡∏ñ‡πâ‡∏≤‡∏à‡∏≥‡πÄ‡∏õ‡πá‡∏ô</li><li>nsaids ‡∏ñ‡πâ‡∏≤‡∏õ‡∏ß‡∏î‡∏°‡∏≤‡∏Å ‡πÜ</li><li>‡∏´‡∏≤‡∏Å‡∏°‡∏µ‡∏õ‡∏±‡∏ç‡∏´‡∏≤‡πÑ‡∏ï‡πÅ‡∏ö‡∏ö biopsy proven ‡πÅ‡∏•‡πâ‡∏ß‡∏Å‡πá‡∏≠‡∏≤‡∏à‡∏ï‡πâ‡∏≠‡∏á aggressive immunosupression</li></ul></li></ul></article><hr><div class=page-end id=footer><div class=backlinks-container><h3>Backlinks</h3><ul class=backlinks><li><a href=/ data-ctx="notes/25 - SLE" data-src=/ class=internal-link>_index</a></li><li><a href=/notes/20-Synovial-Analysis/ data-ctx="notes/25 - SLE" data-src=/notes/20-Synovial-Analysis class=internal-link>20 - Synovial Analysis</a></li><li><a href=/notes/22-RA/ data-ctx="notes/25 - SLE" data-src=/notes/22-RA class=internal-link>22 - RA</a></li></ul></div><div><script async src=https://cdn.jsdelivr.net/npm/d3@6.7.0/dist/d3.min.js integrity="sha256-+7jaYCp29O1JusNWHaYtgUn6EhuP0VaFuswhNV06MyI=" crossorigin=anonymous></script><h3>Interactive Graph</h3><div id=graph-container></div><style>:root{--g-node:var(--secondary);--g-node-active:var(--primary);--g-node-inactive:var(--visited);--g-link:var(--outlinegray);--g-link-active:#5a7282}</style><script src=https://quartz.jzhao.xyz/js/graph.6579af7b10c818dbd2ca038702db0224.js></script></div></div><div id=contact_buttons><footer><p>Made by Harit Jeamvijit using <a href=https://github.com/jackyzha0/quartz>Quartz</a>, ¬© 2023</p><ul><li><a href=https://quartz.jzhao.xyz/>Home</a></li><li><a href=https://github.com/akumaharit/>GitHub</a></li></ul></footer></div></div></body></html>